Women with irritable bowel syndrome with constipation and chronic idiopathic constipation who are younger than 55 and meet specific guidelines may now be able to access tegaserod under a treatment investigational new drug protocol.
Women with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) who are younger than 55 years old and meet specific guidelines may now be able to access tegaserod (Zelnorm, Novartis) under a treatment investigational new drug (IND) protocol. The FDA has announced it will permit restricted use of the drug for women who meet the age requirement, have no preexisting heart conditions, and are in critical need of the medication. Tegaserod will not be available for general use. Physicians who have patients that meet the criteria can contact Novartis at (888)-669-6682.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.